In this regard, evidence stemming from the study of experimental models of autoimmunity, chronic inflammation, fetomaternal tolerance, and tumor growth provides fundamental insights into the critical role of this lectin and its specific glycosylated ligands in maintaining and restoring immune tolerance and homeostasis, thus encouraging future implementation of Gal-1-based therapies in CeD patients. Here, LGALS1 is linked to Autoimmunity.